tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-33-39tumors-340Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSСовременная тактика лечения злокачественных глиом головного мозга и случай полного ответа опухоли на фоне длительного приема бевацизумабаModern tactics of treatment of malignant glyom of the brain and the case of the complete answer of the tumor on the background of the long-term reception of bevacizumabМуфазаловФ. Ф.MufazalovF. F.

д.м.н., профессор, заместитель главного врача

MD, Professor, Deputy Chief Physician

prffm@mail.ruАббасоваР. Р.AbbasovaR. R.

к.м.н., заведующая радиологическим отделением № 2

PhD in Medical sciences, Head of the Radiological Department No. 2

abbasovarr@onkorb.ruМуфазаловаН. А.MufazalovaN. A.

д.м.н., профессор кафедры фармакологии № 1 с курсом клинической фармакологии

MD, Professor of the Department of Pharmacology No. 1 with the course of clinical pharmacology

mufazalovanatalya@yandex.ruГончароваО. В.GoncharovaO. V.

к.м.н., врач-радиотерапевт радиологического отделения № 2

PhD in Medical sciences, radiotherapeutist of Department No. 2

olvlgo79@gmail.comСафинаЛ. Х.SafinaL. Kh.

врач-радиотерапевт радиологического отделения № 2

radiotherapeutist of Department No. 2

safina.oncotrial@gmail.comМуфазаловаЛ. Ф.MufazalovaL. F.

к.м.н., врач-радиотерапевт радиологического отделения № 2

PhD in Medical sciences, radiotherapeutist of Department No. 2

lya-mufazalova@ya.ruГУЗ «Республиканский клинический онкологический диспансер», УфаРоссияRepublican Clinical Oncology Center, UfaRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет», УфаРоссияBashkirian State Medical University, UfaRussian Federation201720072017023339Copyright © Муфазалов Ф.Ф., Аббасова Р.Р., Муфазалова Н.А., Гончарова О.В., Сафина Л.Х., Муфазалова Л.Ф., 20172017Муфазалов Ф.Ф., Аббасова Р.Р., Муфазалова Н.А., Гончарова О.В., Сафина Л.Х., Муфазалова Л.Ф.Mufazalov F.F., Abbasova R.R., Mufazalova N.A., Goncharova O.V., Safina L.K., Mufazalova L.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/340

Глиомы являются широко распространенными первичными опухолями головного мозга у взрослых. При этом глиомы высокой степени анаплазии характеризуются неутешительным прогнозом, несмотря на современные подходы к лечению. В связи с этим безусловный интерес представляют случаи длительного безрецидивного течения заболевания, применяемые схемы лечения и контроля над глиомами высокой степени анаплазии. Исключительный интерес представляет препарат бевацизумаб, который в нашей клинической практике позволил обеспечить пациенту безрецидивный период при глиоме высокой степени злокачественности с 2012 года по настоящее время. 

Gliomas are common primary brain tumors in adults. This high degree of glioma malignancy is characterized by a disappointing outlook, despite the modern approaches to treatment. Therefore cases of prolonged relapse-free period of the disease, as well as treatment regimen and control regimen concerning gliomas with high degree of anaplasia are of exceptional interest. Even more exceptionally interesting is the drug bevacizumab, which in our clinical practice allowed to provide the patient with the diseasefree high-grade glioma from 2012 year to the present. 

анапластическая астроцитомаглиомыбевацизумабanaplastic astrocytomagliomabevacizumabReferencesBrierley B.B. Fighting tumour with humour, The lancet Oncology, 2015, Vol. 16, No. 8, pp. 895–896.Brierley B.B. Fighting tumour with humour, The lancet Oncology, 2015, Vol. 16, No. 8, pp. 895–896.Huang W. J., Chen W.W., Zhang X. Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches, Oncol. Lett., 2016, Vol. 12, No. 4, pp. 2283–2288.Huang W. J., Chen W.W., Zhang X. Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches, Oncol. Lett., 2016, Vol. 12, No. 4, pp. 2283–2288.Anvari K., Seilanian T. M, Shahidsales S., Motlagh F. Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran, Iran J. Cancer Prev., 2016, Vol. 9, pp. 4.Anvari K., Seilanian T. M, Shahidsales S., Motlagh F. Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran, Iran J. Cancer Prev., 2016, Vol. 9, pp. 4.Bent M. J., Taal W. Bevacizumab alone or in combination with chemotherapy in glioblastomas? The lancet Oncology, 2014, Vol. 15, No. 11, pp. 473–474.Bent M. J., Taal W. Bevacizumab alone or in combination with chemotherapy in glioblastomas? The lancet Oncology, 2014, Vol. 15, No. 11, pp. 473–474.Ricard D., Idbaih A., Ducray F. et al. Primary brain tumours in adults, Lancet, 2012, Vol. 379, No. 9830, pp. 1984–1996.Ricard D., Idbaih A., Ducray F. et al. Primary brain tumours in adults, Lancet, 2012, Vol. 379, No. 9830, pp. 1984–1996.Stupp R., Brada M., van den Bent M. J., Tonn J. C. et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2014, Vol. 25, No. 3, pp. 93–101.Stupp R., Brada M., van den Bent M. J., Tonn J. C. et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2014, Vol. 25, No. 3, pp. 93–101.Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2015. С. 250. [Kaprin A. D., Starinskij V. V., Petrova G. V. (eds.) Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost’ I smertnost’), Moscow: filial FGBU “FMIC im. P. A. Gercena” Minzdrava Rossii, 2015, p. 250. (In Russ.)].Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2015. С. 250. [Kaprin A. D., Starinskij V. V., Petrova G. V. (eds.) Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost’ I smertnost’), Moscow: filial FGBU “FMIC im. P. A. Gercena” Minzdrava Rossii, 2015, p. 250. (In Russ.)].Khan L., Soliman H., Sahgal A. et al. External beam radiation dose escalation for high grade glioma, Cochrane Database Syst Rev., 2016, Vol. 19, No. 8. p. CD011475.Khan L., Soliman H., Sahgal A. et al. External beam radiation dose escalation for high grade glioma, Cochrane Database Syst Rev., 2016, Vol. 19, No. 8. p. CD011475.Killela P. J., Pirozzi Ch. J., Reitman Z. J., Jones S., Rasheed B.A., Lipp E., Friedman H., Friedman A.H., He Y., McLendon R. E., Bigner D. D., Yan H. The genetic landscape of anaplastic astrocytoma, Oncotarget, 2013, Vol. 5, No. 6, pp. 1452–1457.Killela P. J., Pirozzi Ch. J., Reitman Z. J., Jones S., Rasheed B.A., Lipp E., Friedman H., Friedman A.H., He Y., McLendon R. E., Bigner D. D., Yan H. The genetic landscape of anaplastic astrocytoma, Oncotarget, 2013, Vol. 5, No. 6, pp. 1452–1457.Анохина Ю. Е., Гайдар Б. В., Мартынов Б. В., Алексеев Д. Е., Свистов Д. В., Папаян Г. В. Влияние объема хирургического вмешательства с применением интраоперационной флуоресцентной диагностики на течение послеоперационного периода у пациентов со злокачественными глиомами головного мозга // Российский нейрохирургический журнал имени профессора А.Л. Поленова. 2014. Т. VI. № 2. С. 22–28. [Anokhina Yu.E., Gaydar B.V., Martynov B.V., Alekseev D.E., Svistov D.V., Papayan G. Vliyanie ob”ema khirurgicheskogo vmeshatel’stva s primeneniem intraoperatsionnoy fluorestsentnoy diagnostiki na techenie posleoperatsionnogo perioda u ptsientov so zlokachestvennymi gliomami golovnogo mozga. Rossiyskiy neyrokhirurgicheskiy zhurnal imeni professora A. L. Polenova, 2014, Vol. 4, No. 2, pp. 22–28. (In Russ.)].Анохина Ю. Е., Гайдар Б. В., Мартынов Б. В., Алексеев Д. Е., Свистов Д. В., Папаян Г. В. Влияние объема хирургического вмешательства с применением интраоперационной флуоресцентной диагностики на течение послеоперационного периода у пациентов со злокачественными глиомами головного мозга // Российский нейрохирургический журнал имени профессора А.Л. Поленова. 2014. Т. VI. № 2. С. 22–28. [Anokhina Yu.E., Gaydar B.V., Martynov B.V., Alekseev D.E., Svistov D.V., Papayan G. Vliyanie ob”ema khirurgicheskogo vmeshatel’stva s primeneniem intraoperatsionnoy fluorestsentnoy diagnostiki na techenie posleoperatsionnogo perioda u ptsientov so zlokachestvennymi gliomami golovnogo mozga. Rossiyskiy neyrokhirurgicheskiy zhurnal imeni professora A. L. Polenova, 2014, Vol. 4, No. 2, pp. 22–28. (In Russ.)].Thakkar J. P., Dolecek T. A., Horbinski C., Ostrom Q. T. et al. Epidemiologic and molecular prognostic review of glioblastoma, Cancer Epidemiol. Biomarkers Prev., 2014, Vol. 23, No. 10, pp. 1985–1986.Thakkar J. P., Dolecek T. A., Horbinski C., Ostrom Q. T. et al. Epidemiologic and molecular prognostic review of glioblastoma, Cancer Epidemiol. Biomarkers Prev., 2014, Vol. 23, No. 10, pp. 1985–1986.Granovetter M. Potential treatment for a subtype of glioblastoma tumours, The lancet Oncology, 2016, Vol. 17, No. 5, pp. 1467–1469.Granovetter M. Potential treatment for a subtype of glioblastoma tumours, The lancet Oncology, 2016, Vol. 17, No. 5, pp. 1467–1469.Абсалямова О. В., Алешин В. А., Аникеева О. Ю., Бекяшев А. Х. Клинические рекомендации по диагностике и лечению больных с первичными опухолями головного мозга. 2014. C. 1–60. [Absalyamova O.V., Aleshin V.A., Anikeeva O.Yu., Bekyashev A.Kh. Klinicheskie rekomendatsii po diagnostike i lecheniyu bol’nykh s pervichnymi opukholyami golovnogo mozga, 2014, pp. 1–60. (In Russ.)].Абсалямова О. В., Алешин В. А., Аникеева О. Ю., Бекяшев А. Х. Клинические рекомендации по диагностике и лечению больных с первичными опухолями головного мозга. 2014. C. 1–60. [Absalyamova O.V., Aleshin V.A., Anikeeva O.Yu., Bekyashev A.Kh. Klinicheskie rekomendatsii po diagnostike i lecheniyu bol’nykh s pervichnymi opukholyami golovnogo mozga, 2014, pp. 1–60. (In Russ.)].Roberta R. Does an optimum treatment for high-risk low-grade gliomas exist? The lancet Oncology, 2016, Vol. 17, No. 11, pp. 1467–1469.Roberta R. Does an optimum treatment for high-risk low-grade gliomas exist? The lancet Oncology, 2016, Vol. 17, No. 11, pp. 1467–1469.Bradshaw R., Wickremesekera A. C., Brasch H. D. et al. Glioblastoma multiforme cancer stem cells express components of the renin – angiotensin system, Front. Surg., 2016, No. 3, p. 51.Bradshaw R., Wickremesekera A. C., Brasch H. D. et al. Glioblastoma multiforme cancer stem cells express components of the renin – angiotensin system, Front. Surg., 2016, No. 3, p. 51.Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 2009., Vol. 27, No. 28, pp. 4733–4740.Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 2009., Vol. 27, No. 28, pp. 4733–4740.Yang P., Zhang C., Cai J., You G. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma, Oncotarget., 2016, Vol. 7, No. 48, pp. 80091–80100.Yang P., Zhang C., Cai J., You G. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma, Oncotarget., 2016, Vol. 7, No. 48, pp. 80091–80100.McCracken D. J., Celano E. C., Voloschin A. D., Read W. L., Olson J. J. Phase I trial of dose-escalating metronomic temozolomide plusbevacizumab and bortezomib for patients with recurrent glioblastoma, Neurooncol., 2016, Vol. 130, No. 1, pp. 193–201.McCracken D. J., Celano E. C., Voloschin A. D., Read W. L., Olson J. J. Phase I trial of dose-escalating metronomic temozolomide plusbevacizumab and bortezomib for patients with recurrent glioblastoma, Neurooncol., 2016, Vol. 130, No. 1, pp. 193–201.Beppu T., Terasaki K., Sasaki T., Sato Y. et al. MRI and 11C-methyl-L-methionine PET differentiate Bevacizumab true responders after initiating therapy for recurrent glioblastoma, Clin. Nucl. Med., 2016, Vol. 41, No. 11, pp. 852–857.Beppu T., Terasaki K., Sasaki T., Sato Y. et al. MRI and 11C-methyl-L-methionine PET differentiate Bevacizumab true responders after initiating therapy for recurrent glioblastoma, Clin. Nucl. Med., 2016, Vol. 41, No. 11, pp. 852–857.Song P. J., Lu Q. Y., Li M. Y., Li X., Shen F. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas, J. Biol. Regul. Homeost. Agents, 2016, Vol. 30, No. 3, pp. 833–838.Song P. J., Lu Q. Y., Li M. Y., Li X., Shen F. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas, J. Biol. Regul. Homeost. Agents, 2016, Vol. 30, No. 3, pp. 833–838.Gilbert M. R., Wang M., Aldape K. D., Stupp R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J. Clin. Oncol., 2013, Vol. 31, No. 32, pp. 4085–4091.Gilbert M. R., Wang M., Aldape K. D., Stupp R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J. Clin. Oncol., 2013, Vol. 31, No. 32, pp. 4085–4091.van den Bent M. J. Treatment of newly diagnosed anaplastic gliomas, EJC, 2007, Vol. 5, No. 5, pp. 409–410.van den Bent M. J. Treatment of newly diagnosed anaplastic gliomas, EJC, 2007, Vol. 5, No. 5, pp. 409–410.Field K.M., Jordan J. T., Wen P. Y., Rosenthal M. A., Reardon D. A. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies, Cancer, 2015, Vol. 121, No. 7, pp. 997–1007.Field K.M., Jordan J. T., Wen P. Y., Rosenthal M. A., Reardon D. A. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies, Cancer, 2015, Vol. 121, No. 7, pp. 997–1007.Plate K.H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, 1992, Vol. 359, No. 6398, pp. 845–848.Plate K.H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, 1992, Vol. 359, No. 6398, pp. 845–848.Lamszus K., Ulbricht U., Matschke J., Brockmann M. A., Fillbrandt R., Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A, Clin. Cancer Res., 2003, Vol. 9., No. 4, pp. 1399–1405.Lamszus K., Ulbricht U., Matschke J., Brockmann M. A., Fillbrandt R., Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A, Clin. Cancer Res., 2003, Vol. 9., No. 4, pp. 1399–1405.Hesselager G., Holland E. C. Using Mice to Decipher the Molecular Genetics of Brain Tumors, Neurosurgery, 2003, Vol. 53, pp. 685–694.Hesselager G., Holland E. C. Using Mice to Decipher the Molecular Genetics of Brain Tumors, Neurosurgery, 2003, Vol. 53, pp. 685–694.Shahzad R., Belal F., Doll D. C. Bevacizumab alone or in combination with chemotherapy in glioblastomas? The lancet Oncology, 2014, Vol. 15, No. 11, pp. 472–473.Shahzad R., Belal F., Doll D. C. Bevacizumab alone or in combination with chemotherapy in glioblastomas? The lancet Oncology, 2014, Vol. 15, No. 11, pp. 472–473.Roger Y., Tsang M. D. Glioblastoma role of bevacizumab in newly diagnosed glioblastoma, Landmarks Reports of recent research Report from the ASCO annual meeting, 2013, Vol. 12, No. 3, pp. 26–28.Roger Y., Tsang M. D. Glioblastoma role of bevacizumab in newly diagnosed glioblastoma, Landmarks Reports of recent research Report from the ASCO annual meeting, 2013, Vol. 12, No. 3, pp. 26–28.Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, Neuro Oncology, 2005, No. 7, pp. 685–694.Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, Neuro Oncology, 2005, No. 7, pp. 685–694.Zhang G., Huang S., Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme, Journal of clinical neuroscience, 2012, Vol. 19, Nol. 2, pp. 1636–1640.Zhang G., Huang S., Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme, Journal of clinical neuroscience, 2012, Vol. 19, Nol. 2, pp. 1636–1640.Wang Y., Xing D., Zhao M., Wang J., Yang Y. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review, PLoS One, 2016, Vol. 11, No. 3.Wang Y., Xing D., Zhao M., Wang J., Yang Y. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review, PLoS One, 2016, Vol. 11, No. 3.Nelson S. J., Li Y., Lupo J.M., Olson M. et al. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab, J. Neurooncol., 2016, Vol. 130, No. 1, pp. 171–179.Nelson S. J., Li Y., Lupo J.M., Olson M. et al. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab, J. Neurooncol., 2016, Vol. 130, No. 1, pp. 171–179.Kelong H., Melanie R., Wolfgang W., Lauren A. et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literaturebased meta-analysis from 91 trials, Neuro-Oncology, 2014, Vol. 16, No. 5, pp. 696–706.Kelong H., Melanie R., Wolfgang W., Lauren A. et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literaturebased meta-analysis from 91 trials, Neuro-Oncology, 2014, Vol. 16, No. 5, pp. 696–706.Sathornsumetee S., Reardon D. A., Desjardins A., Quinn J. A. Molecularly targeted therapy for malignant glioma, Cancer, 2007, Vol. 110, No. 1, pp. 13–24.Sathornsumetee S., Reardon D. A., Desjardins A., Quinn J. A. Molecularly targeted therapy for malignant glioma, Cancer, 2007, Vol. 110, No. 1, pp. 13–24.Fukaya R., Ozaki M., Kamamoto D., Tokuda Y. et al. Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long-term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report, Mol. Clin. Oncol., 2016, Vol. 5, No. 4, pp. 417–421.Fukaya R., Ozaki M., Kamamoto D., Tokuda Y. et al. Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long-term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report, Mol. Clin. Oncol., 2016, Vol. 5, No. 4, pp. 417–421.

The authors declare that there are no conflicts of interest present.